-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Although the pharmaceutical industry is often labeled as a recession-resistant, it is not immune to future challenges. Ongoing issues such as constraints on drug pricing and reimbursement (P&R), the evolving regulatory landscape, pressures to innovate, and pressures to address environmental, social, and governance (ESG) issues will continue to pose challenges for the pharmaceutical sector in the coming years. In this “The State of the Biopharmaceutical Industry” report, GlobalData examines the business environment and trends that are going to shape the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-3454 in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-3454 in Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-3454 in Astrocytoma Drug Details: TQB-3454 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2858 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2858 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2858 in Nasopharyngeal Cancer Drug Details: TQB-2858 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HT-6184 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HT-6184 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HT-6184 in Alzheimer's Disease Drug Details: HT-6184 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2858 in Malignant Neoplasms
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2858 in Malignant Neoplasms report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2858 in Malignant Neoplasms Drug Details: TQB-2858 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paclitaxel in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel in Metastatic Breast Cancer Drug Details: Paclitaxel (DHP-107, Liporaxel)...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2618 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2618 in Metastatic Colorectal Cancer Drug Details: TQB-2618 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2618 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2618 in Hepatocellular Carcinoma Drug Details: TQB-2618 is under development for the...